Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3476-3481, July 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Z.-G.
Right arrow Articles by Rustum, Y. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Z.-G.
Right arrow Articles by Rustum, Y. M.

Effects of Diastereoisomers of 5-Formyltetrahydrofolate on Cellular Growth, Sensitivity to 5-Fluoro-2'-deoxyuridine, and Methylenetetrahydrofolate Polyglutamate Levels in HCT-8 Cells1

Zheng-Gang Zhang and Youcef M. Rustum2

Department of Experimental Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263

We investigated the biological activities of the natural and unnatural diastereoisomers of 5-formyltetrahydrofolate [(6S)- and (6R)-5-HCO-H4PteGlu, respectively, both 99.99% pure], using a human ileocecal carcinoma cell line (HCT-8). Optimal cell growth could be supported by (6S)-5-HCO-H4PteGlu at concentrations as low as 1 nM. (6R)-5-HCO-H4PteGlu did not support growth. Modulation of the in vitro cytotoxicity of 5-fluoro-2'-deoxyuridine (FdUrd) and intracellular (6R)-5,10-methylenetetrahydrofolates [(6R)-CH2H4PteGlun] pools by (6S)- and (6R)-5-HCO-H4PteGlu was determined with cells growing in 1 nM (6S)-5-HCO-H4PteGlu. For the control cells, the concentration of FdUrd inhibiting growth by 50% was 179 nM and the total (6R)-CH2H4PteGlun was 2.3 pmol/106 cells. When cells were treated with (6S)-5-HCO-H4PteGlu for 24 h, the 50% inhibition concentration of FdUrd decreased with increasing concentrations of (6S)-5-HCO-H4PteGlu, and reached a plateau of 36 nM when (6S)-5-HCO-H4PteGlu was ≥1 µM. The total (6R)-CH2H4PteGlun pools were augmented by (6S)-5-HCO-H4PteGlu dose dependently up to 6.8 pmol/106 cells at 1 µM (6S)-5-HCO-H4PteGlu. (6S)-5-HCO-H4PteGlu at 10 µM did not further increase the total (6R)-CH2H4PteGlun, but induced a marked shift in the polyglutamate chain length distribution, with an increase in tri- and tetra-, and a decrease in penta-, hexa-, and heptaglutamate. The down-shift of (6R)-CH2H4-PteGlun polyglutamate chain length observed after (6S)-5-HCO-H4PteGlu treatment did not impair the modulation of FdUrd cytotoxicity. Thus shorter chain (6R)-CH2H4PteGlun (n = 3–4) function as well as longer ones (n = 5–7). (6R)-5-HCO-H4PteGlu, at 200 µM, had no effect on the cytotoxicity of FdUrd, the total (6R)-CH2H4PteGlun level, or chain length distribution in the presence or absence of additional (6S)-5-HCO-H4PteGlu. These results suggest that the high plasma (6R)-5-HCO-H4PteGlu concentrations (up to 200 µM) achieved in patients following i.v. administration of high doses of (6R,S)-5-HCO-H4PteGlu probably do not have adverse effects on the modulation of antitumor activity of FdUrd or 5-fluorouracil. Since the optimal dose and schedule of (6S)-5-HCO-H4PteGlu for modulation of fluoropyrimidines may vary from one cell type to another, introducing high doses of (6R,S)-5-HCO-H4PteGlu in patients so that the plasma concentration of the natural isomer reaches 10 µM is still recommended.

1 Supported by Program Grant CA21071 and Cancer Center Core Grant CA16056 from the National Cancer Institute.

2 To whom requests for reprints should be addressed, at Department of Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 1/22/91. Accepted 4/18/91.




This article has been cited by other articles:


Home page
The OncologistHome page
J. Jolivet, A. Dayan, M. Beauchemin, D. Chahla, A. Mamo, and R. Bertrand
Biochemical and Molecular Studies of Human Methenyltetrahydrofolate Synthetase
Oncologist, August 1, 1996; 1(4): 248 - 253.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Chen, H. Qi, J. Korenberg, T. A. Garrow, Y.-J. Choi, and B. Shane
Purification and Properties of Human Cytosolic Folylpoly-gamma -glutamate Synthetase and Organization, Localization, and Differential Splicing of Its Gene
J. Biol. Chem., May 31, 1996; 271(22): 13077 - 13087.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
J Jolivet, A Dayan, M Beauchemin, D Chahla, A Mamo, and R Bertrand
Biochemical and molecular studies of human methenyltetrahydrofolate synthetase
Stem Cells, January 1, 1996; 14(1): 33 - 40.
[Abstract]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.